Us Congress 2023-2024 Regular Session

Us Congress House Bill HB7188

Introduced
2/1/24  
Refer
2/1/24  
Refer
2/2/24  

Caption

Shandra Eisenga Human Cell and Tissue Product Safety Act

Impact

If enacted, HB 7188 will significantly impact the regulations surrounding human cell and tissue products. By requiring the Secretary to initiate educational programs and update existing donor eligibility guidelines, the bill hopes to reduce health risks and improve the overall safety of transplant procedures. This legislation will also enable ongoing communication between stakeholders in the tissue transplant community, including healthcare providers and industry experts, thereby promoting regulatory predictability and ensuring that safety practices remain aligned with scientific developments.

Summary

House Bill 7188, titled the 'Shandra Eisenga Human Cell and Tissue Product Safety Act', aims to enhance public and healthcare provider awareness regarding the risks and benefits associated with human cell and tissue product transplants. The bill mandates the Secretary of Health and Human Services to conduct a nationwide education campaign and to develop informational materials that focus on organ, tissue, and eye donation, as well as the availability of donor screening tests. This effort seeks to improve understanding among both professionals and families impacted by transplant decisions.

Sentiment

The sentiment towards HB 7188 appears generally positive among health advocates and transplant organizations who recognize the importance of informed decision-making in advancing public health policies. Ensuring that both providers and the public are educated about the benefits and risks associated with transplants aligns with broader goals of enhancing healthcare outcomes and patient safety. However, there may be apprehensions regarding the adequacy of funding and resources needed to execute these educational initiatives effectively.

Contention

There were discussions surrounding the potential challenges of implementation and the administrative burden placed upon the Secretary of Health and Human Services. Some critics may argue that the bill requires a significant investment in public outreach that could distract from other pressing healthcare priorities. Additionally, determining the effectiveness of the awareness campaign and ensuring compliance among healthcare providers will be key factors that will need monitoring to assess the long-term impact of the legislation.

Companion Bills

US SB3733

Same As Shandra Eisenga Human Cell and Tissue Product Safety Act

Previously Filed As

US SB3733

Shandra Eisenga Human Cell and Tissue Product Safety Act

US HB1082

Shandra Eisenga Human Cell and Tissue Product Safety Act

US HB340

The HCT/P Modernization Act of 2025This bill requires the Food and Drug Administration (FDA) to provide information to stakeholders and report on the regulation of human cell and tissue products, also referred to as human cells, tissues, or cellular or tissue-based products (HCT/Ps), which are articles containing or consisting of human cells or tissues that are intended for use in a human recipient.The bill requires the FDA to conduct workshops to educate stakeholders and facilitate discussion with them on advancing the science and regulation of human cell and tissue products. The FDA must establish a public docket to receive written comments on this topic, and submit to Congress a report with recommendations on regulating these products. Additionally, the bill requires the FDA to publish on its website educational materials about the Tissue Reference Group and best practices for obtaining a recommendation about products from them. Also, annually for three years, the FDA must publish on its website information on the inquiries submitted and average response times for the Tissue Reference Group, as well as the number of human cell and tissue manufacturers that have registered with the FDA and the number of inspections the FDA has conducted with respect to these manufacturers since 2019. (The Tissue Reference Group is a working group within the FDA that receives product-specific questions from, and provides recommendations for, stakeholders on the regulation of human cell and tissue products under the FDA’s rules.) 

US HB8251

The HCT/P Modernization Act of 2024

US HB7265

Child Suicide Prevention and Lethal Means Safety Act

US HB7268

DeOndra Dixon INCLUDE Project Act of 2024

US HB7406

DeOndra Dixon INCLUDE Project Act of 2024

US HB9161

Health Equity and Accountability Act of 2024 CHANGE Act Correcting Hurtful and Alienating Names in Government Expression Act Immigrants’ Mental Health Act of 2024 Menstrual Equity For All Act of 2024 Real Education and Access for Healthy Youth Act of 2024 Data To Save Moms Act CARE for Moms Act Community Access, Resources, and Empowerment for Moms Act Senior Hunger Prevention Act of 2024 Universal School Meals Program Act of 2024

US HB7891

Kids Online Safety Act

US HB7134

Invest in Child Safety Act of 2024

Similar Bills

CA SB493

District agricultural associations: secretary-managers: compensation.

LA HB528

Reforms the organizational structure for the Department of Transportation and Development including its duties, powers, and responsibilities of officers and employees (EN INCREASE SD EX See Note)

MO HB2798

Modifies the "Missouri Family Trust Company Act"

CA AB1044

Elections: Secretary of State.

AR SB63

To Amend Arkansas Law Concerning Reports By The Secretaries Of Cabinet-level Departments On The State Of Their Departments.

CA AB1206

Voter registration database: Electronic Registration Information Center.

CA SB297

Elections: initiatives and referenda: withdrawal.

CA AB1004

Secretary of State: voter information Internet Web site.